The prevalence, incidence and natural history of primary sclerosing cholangitis in an ethnically diverse population.
Elaine Toy, Sripriya Balasubramanian, Carlo Selmi...
https://pubmed.ncbi.nlm.nih.gov/21767410/Actively Recruiting
Led by Arbor Research Collaborative for Health · Updated on 2026-07-14
1000
Participants Needed
12
Research Sites
N/A
Total Duration
Primary sclerosing cholangitis PSC is a rare liver disease that damages the bile ducts, which carry bile from the liver to the small intestine. This trial focuses on children and young adults aged 2 to 25 years with PSC, aiming to better understand how the disease progresses, its impact on daily life, and factors influencing its severity. Researchers also seek to clarify the relationship between PSC and inflammatory bowel disease IBD and to explore new imaging techniques and biomarkers related to PSC. Participants contribute medical data, DNA, and other biological samples to help identify disease characteristics and risk factors. This is an observational study where no treatment is given instead, researchers collect information over time to observe disease progression and impacts. Some participants will undergo advanced imaging to measure liver fibrosis and bile duct injury, which are correlated with other markers to predict disease progression. Throughout the study, participants will have assessments of liver function, symptoms, and quality of life. Samples like blood and stool are collected to build a biobank for future research. The main outcome is to characterize PSC types and their relationship with IBD and autoimmune hepatitis. Secondary measures include symptom effects, imaging results, and specimen collection. The study may last up to 10 years, with ongoing follow-up to gather comprehensive data about pediatric PSC.
CONDITIONS
Primary Sclerosing Cholangitis in Children
M
Melissa Sexton, BBA, CCRP
M
Melissa Sexton, BBA, CCRP
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Arbor Research Collaborative for Health
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Have more questions? Get in touch with our team for quick support
Elaine Toy, Sripriya Balasubramanian, Carlo Selmi...
https://pubmed.ncbi.nlm.nih.gov/21767410/Amanda Ricciuto, Binita M Kamath, Anne M Griffiths
https://pubmed.ncbi.nlm.nih.gov/29594739/Vratislav Smolka, Eva Karaskova, Oksana Tkachyk...
https://pubmed.ncbi.nlm.nih.gov/27498582/Tamir Miloh, Ronen Arnon, Benjamin Shneider...
https://pubmed.ncbi.nlm.nih.gov/19121649/Kiran Bambha, W Ray Kim, Jayant Talwalkar...
https://pubmed.ncbi.nlm.nih.gov/14598252/Mark Deneau, M Kyle Jensen, John Holmen...
https://pubmed.ncbi.nlm.nih.gov/23686586/R Olsson, A Danielsson, G Järnerot...
https://pubmed.ncbi.nlm.nih.gov/2013375/M Wilschanski, P Chait, J A Wade...
https://pubmed.ncbi.nlm.nih.gov/7590657/Ariel E Feldstein, Jean Perrault, Mounif El-Youssif...
https://pubmed.ncbi.nlm.nih.gov/12830004/Pamela L Valentino, Shanna Wiggins, Sarah Harney...
https://pubmed.ncbi.nlm.nih.gov/27504812/Arbor Research Collaborative for Health
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborating Sponsor